Literature DB >> 31391744

IOTA Simple Ultrasound Rules for Triage of Adnexal Mass: Experience from South India.

Jyothi Shetty1, Aruna Saradha1, Deeksha Pandey1, Rajeshwari Bhat1, Sunanda Bharatnur1.   

Abstract

OBJECTIVE: To assess the diagnostic performance of International Ovarian Tumor Analysis (IOTA) simple ultrasound rules to discriminate adnexal masses as benign or malignant.
METHODS: A cross-sectional prospective study was conducted on women scheduled for elective surgery due to adnexal masses. Ultrasound examiner systematically assessed the tumors according to the IOTA simple rules to determine the risk of the tumor being malignant. If the simple rules yielded inconclusive result, pattern recognition was used to categorize the mass. Results were then compared with histologic findings after surgery. Diagnostic performance was assessed by calculating sensitivity and specificity.
RESULTS: Two hundred and five women undergoing surgery were included. The rules were applicable in 183 (89.3%) of the tumors; and for these tumors, sensitivity was 92.8% (95% CI 77-99%) and specificity was 92.9% (95% CI 88-96.4%). Of the tumors, 144 were benign and 39 were malignant. The simple rules yielded inconclusive results in 22 masses which were analyzed by pattern recognition.
CONCLUSION: IOTA simple rules provide excellent discrimination between benign and malignant adnexal masses.

Entities:  

Keywords:  Adnexal mass; Benign ovarian tumor; IOTA simple rules; Ultrasound

Year:  2019        PMID: 31391744      PMCID: PMC6661039          DOI: 10.1007/s13224-019-01229-z

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  21 in total

Review 1.  Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group.

Authors:  D Timmerman; L Valentin; T H Bourne; W P Collins; H Verrelst; I Vergote
Journal:  Ultrasound Obstet Gynecol       Date:  2000-10       Impact factor: 7.299

2.  Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group.

Authors:  D Timmerman; B Van Calster; A C Testa; S Guerriero; D Fischerova; A A Lissoni; C Van Holsbeke; R Fruscio; A Czekierdowski; D Jurkovic; L Savelli; I Vergote; T Bourne; S Van Huffel; L Valentin
Journal:  Ultrasound Obstet Gynecol       Date:  2010-08       Impact factor: 7.299

3.  External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group.

Authors:  Caroline Van Holsbeke; Ben Van Calster; Lil Valentin; Antonia C Testa; Enrico Ferrazzi; Ioannis Dimou; Chuan Lu; Philippe Moerman; Sabine Van Huffel; Ignace Vergote; Dirk Timmerman
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

4.  Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons.

Authors:  M J A Engelen; A G J van der Zee; E G E de Vries; P H B Willemse
Journal:  Cancer Treat Rev       Date:  2006-05-16       Impact factor: 12.111

5.  Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.

Authors:  Ben Van Calster; Dirk Timmerman; Tom Bourne; Antonia Carla Testa; Caroline Van Holsbeke; Ekaterini Domali; Davor Jurkovic; Patrick Neven; Sabine Van Huffel; Lil Valentin
Journal:  J Natl Cancer Inst       Date:  2007-11-13       Impact factor: 13.506

6.  Assessing clinical performance of gynecology residents: sonographic evaluation of adnexal masses based on morphological scoring systems.

Authors:  T S Lee; J W Kim; N H Park; Y S Song; S B Kang; H P Lee
Journal:  Ultrasound Obstet Gynecol       Date:  2005-12       Impact factor: 7.299

7.  Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.

Authors:  Dirk Timmerman; Antonia C Testa; Tom Bourne; Enrico Ferrazzi; Lieveke Ameye; Maja L Konstantinovic; Ben Van Calster; William P Collins; Ignace Vergote; Sabine Van Huffel; Lil Valentin
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

8.  Simple ultrasound-based rules for the diagnosis of ovarian cancer.

Authors:  D Timmerman; A C Testa; T Bourne; L Ameye; D Jurkovic; C Van Holsbeke; D Paladini; B Van Calster; I Vergote; S Van Huffel; L Valentin
Journal:  Ultrasound Obstet Gynecol       Date:  2008-06       Impact factor: 7.299

9.  The accuracy of risk scores in predicting ovarian malignancy: a systematic review.

Authors:  Peggy Geomini; Roy Kruitwagen; Gérard L Bremer; Jeltsje Cnossen; Ben W J Mol
Journal:  Obstet Gynecol       Date:  2009-02       Impact factor: 7.661

10.  Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group.

Authors:  Dirk Timmerman; Lieveke Ameye; Daniela Fischerova; Elisabeth Epstein; Gian Benedetto Melis; Stefano Guerriero; Caroline Van Holsbeke; Luca Savelli; Robert Fruscio; Andrea Alberto Lissoni; Antonia Carla Testa; Joan Veldman; Ignace Vergote; Sabine Van Huffel; Tom Bourne; Lil Valentin
Journal:  BMJ       Date:  2010-12-14
View more
  2 in total

1.  Prospective revalidation of IOTA "two-step", "alternative two-step" and "three-step" strategies for characterization of adnexal masses - An Indian study focussing the radiology context.

Authors:  Shabnam Bhandari Grover; Sayantan Patra; Hemal Grover; Pratima Mittal; Geetika Khanna
Journal:  Indian J Radiol Imaging       Date:  2020-10-15

2.  Early-Stage Ovarian Malignancy Score versus Risk of Malignancy Indices: Accuracy and Clinical Utility for Preoperative Diagnosis of Women with Adnexal Masses.

Authors:  Phichayut Phinyo; Jayanton Patumanond; Panprapha Saenrungmuaeng; Watcharin Chirdchim; Tanyong Pipanmekaporn; Apichat Tantraworasin; Theera Tongsong; Charuwan Tantipalakorn
Journal:  Medicina (Kaunas)       Date:  2020-12-16       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.